Chinese Fibromyalgia Market Growth Analysis 2018 with Pivotal Players as Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, etc. by 2022

Chinese Fibromyalgia Market Report is added on MarketReseacrhFuture.com and it analyzes the worldwide Segmentation and Sub Segmentation. Covered all the information with Top Industry Players, Major Drivers and Mega Trends. Outlet till 2022.

Chinese Fibromyalgia Market Scenario:

Fibromyalgia syndrome co-exists with other painful conditions, such as migraine and other types of headaches, temporomandibular joint disorders, irritable bowel syndrome (IBS), and interstitial cystitis. The treatment of fibromyalgia includes both targeted and symptomatic approach. Till date, there are only three FDA approved drugs for the fibromyalgia treatment, i.e., Lyrica (PFIZER), Cymbalta (Eli Lilly and Company), and Savella (Allergan plc). However, there are few other drugs prescribed by physicians to control the symptoms of fibromyalgia such as pain relievers, muscle relaxants, and traditional Chinese medicine. The Chinese fibromyalgia market is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022.

Get Premium Sample copy at https://www.marketresearchfuture.com/sample_request/5630

Growing geriatric population, increasing cases of rheumatic diseases, growing awareness among the population, and rising incidences of traumatic stress and road accidents are the key factors driving the Chinese fibromyalgia market. According to a study published in the Arthritis Care & Research journal in 2017, fibromyalgia and related symptoms worsen the functional status of individuals with rheumatoid arthritis. Around 15%-30% of patients with rheumatic disorders have co-morbid fibromyalgia syndrome.

Key Players:

Pfizer

GlaxoSmithKline

AstraZeneca

Roche

Astellas Pharma

Eli Lilly and Company

Johnson & Johnson Services

SANOFI and others.

Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

Have Any Query, Ask to Expert at https://www.marketresearchfuture.com/enquiry/5630

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e., 9.9% per year.

Segment:

The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Major TOC of Chinese Fibromyalgia Market Research Report- Forecast to 2022:

1  Report Prologue

2  Market Introduction

3  Research Methodology

4  Market Dynamics

5  Market Factor Analysis

6  Chinese Fibromyalgia Market, By Diagnosis

7  Global and China Fibromyalgia Market, By Treatment

8  Chinese Fibromyalgia Market, By End Users

9  Chinese Fibromyalgia Market, By Regions

10  Competitive landscape

11  Company Profiles

12  Conclusion

13  Appendix

Get Stunning Discount at https://www.marketresearchfuture.com/check-discount/5630

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.